Management of hypersensitivity to platinum- and taxane-based chemotherapy: CEPO review and clinical recommendations

Current Oncology

Volumn 21, Issue 4, 2014, Pages

  Boulanger, J ^a   Boursiquot, J N ^b   Cournoyer, G ^c   Lemieux, J ^b   Masse, M S ^d   Almanric, K ^e   Guay, Marie Pascale ^f  

^a 2535 boulevard Laurier   (Canada)

^b LAVAL UNIVERSITY   (Canada)

^c Hôpital Régional de Saint Jérôme CSSS de Saint Jérôme   (Canada)

^d NOTRE DAME HOSPITAL   (Canada)

^e Hôpital Cité de la Santé et Direction de Santé Publique de Laval   (Canada)

^f MCGILL UNIVERSITY   (Canada)

Author keywords

Chemotherapy; Desensitization; Hypersensitivity reactions; Management; Platinum salts; Skin testing; Taxanes

Indexed keywords

EID: 84905709235     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.21.1966     Document Type: Article

References (77)

1. Castells M, Sancho-Serra MD, Simarro M. Hypersensitivity to antineoplastic agents: mechanisms and treatment with rapid desensitization. Cancer Immunol Immunother 2012:1575-84.
2. Pagani M. The complex clinical picture of presumably allergic side effects to cytostatic drugs: symptoms, pathomechanism, reexposure, and desensitization. Med Clin North Am 2010;94:835-52,xiii.
3. Demoly P, Bousquet J. Drug allergy diagnosis work up. Allergy 2002;57(suppl 72):37-40.
4. Shepherd GM. Hypersensitivity reactions to chemotherapeutic drugs. Clin Rev Allergy Immunol 2003;24:253-62.
5. Chung CH. Managing premedications and the risk for reactions to infusional monoclonal antibody therapy. Oncologist 2008;13:725-32.
6. Ozols RF, Bundy BN, Greer BE, et al. Phase iii trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage iii ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2003;21:3194-200.
7. Cook DJ, Guyatt GH, Laupacis A, Sackett DL. Rules of evidence and clinical recommendations on the use of antithrombotic agents. Chest 1992;102(suppl):305S-11S.
8. Syrigou E, Triantafyllou O, Makrilia N, et al. Acute hypersensitivity reactions to chemotherapy agents: an overview. Inflamm Allergy Drug Targets 2010;9:206-13.
9. Makrilia N, Syrigou E, Kaklamanos I, Manolopoulos L, Saif MW. Hypersensitivity reactions associated with platinum antineoplastic agents: a systematic review. Met Based Drugs 2010;2010:pii:207084.
10. O'Cearbhaill R, Zhou Q, Iasonos A, et al. The prophylactic conversion to an extended infusion schedule and use of premedication to prevent hypersensitivity reactions in ovarian cancer patients during carboplatin retreatment. Gynecol Oncol 2010;116:326-31.
11. Bautista MA, Stevens WT, Chen CS, Curtis BR, Aster RH, Hsueh CT. Hypersensitivity reaction and acute immunemediated thrombocytopenia from oxaliplatin: two case reports and a review of the literature. J Hematol Oncol 2010;3:12.
12. Dizon DS, Sabbatini PJ, Aghajanian C, Hensley ML, Spriggs DR. Analysis of patients with epithelial ovarian cancer or fallopian tube carcinoma retreated with cisplatin after the development of a carboplatin allergy. Gynecol Oncol 2002;84:378-82.
13. Gadducci A, Tana R, Teti G, Zanca G, Fanucchi A, Genazzani AR. Analysis of the pattern of hypersensitivity reactions in patients receiving carboplatin retreatment for recurrent ovarian cancer. Int J Gynecol Cancer 2008;18:615-20.
14. Schwartz JR, Bandera C, Bradley A, et al. Does the platinumfree interval predict the incidence or severity of hypersensitivity reactions to carboplatin? The experience from Women and Infants' Hospital. Gynecol Oncol 2007;105:81-3.
15. Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E, et al. Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol 2010;28:3323-9.
16. Markman M, Moon J, Wilczynski S, et al. Single agent carboplatin versus carboplatin plus pegylated liposomal doxorubicin in recurrent ovarian cancer: final survival results of a swog (S0200) phase 3 randomized trial. Gynecol Oncol 2010;116:323-5.
17. Gobel BH. Chemotherapy-induced hypersensitivity reactions. Oncol Nurs Forum 2005;32:1027-35.
18. Shukunami K, Kurokawa T, Kawakami Y, Kubo M, Kotsuji F. Hypersensitivity reactions to intraperitoneal administration of carboplatin in ovarian cancer: the first report of a case. Gynecol Oncol 1999;72:431-2.
19. Markman M, Kennedy A, Webster K, Kulp B, Peterson G, Belinson J. Paclitaxel-associated hypersensitivity reactions: experience of the gynecologic oncology program of the Cleveland Clinic Cancer Center. J Clin Oncol 2000;18:102-5.
20. Weiss RB. Hypersensitivity reactions. Semin Oncol 1992;19:458-77.
21. Sendo T, Sakai N, Itoh Y, et al. Incidence and risk factors for paclitaxel hypersensitivity during ovarian cancer chemotherapy. Cancer Chemother Pharmacol 2005;56:91-6.
22. Kloover JS, den Bakker MA, Gelderblom H, van Meerbeeck JP. Fatal outcome of a hypersensitivity reaction to paclitaxel: a critical review of premedication regimens. Br J Cancer 2004;90:304-5.
23. Moisidis C, Mobus V. Erythema multiforme major following docetaxel. Arch Gynecol Obstet 2005;271:267-9.
24. Goldberg A, Confino-Cohen R, Fishman A, Beyth Y, Altaras M. A modified, prolonged desensitization protocol in carboplatin allergy. J Allergy Clin Immunol 1996;98:841-3.
25. Szebeni J, Muggia FM, Alving CR. Complement activation by Cremophor el as a possible contributor to hypersensitivity to paclitaxel: an in vitro study. J Natl Cancer Inst 1998;90:300-6.
26. Weiss RB, Donehower RC, Wiernik PH, et al. Hypersensitivity reactions from taxol. J Clin Oncol 1990;8:1263-8.
27. O'Dwyer PJ, King SA, Fortner CL, Leyland-Jones B. Hypersensitivity reactions to teniposide (VM-26): an analysis. J Clin Oncol 1986;4:1262-9.
28. Gradishar WJ, Tjulandin S, Davidson N, et al. Phase iii trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005;23:7794-803.
29. Fossella FV, Lee JS, Murphy WK, et al. Phase ii study of docetaxel for recurrent or metastatic non-small-cell lung cancer. J Clin Oncol 1994;12:1238-44.
30. Essayan DM, Kagey-Sobotka A, Colarusso PJ, Lichtenstein LM, Ozols RF, King ED. Successful parenteral desensitization to paclitaxel. J Allergy Clin Immunol 1996;97:42-6.
31. Prieto Garcia A, Pineda de la Losa F. Immunoglobulin E- mediated severe anaphylaxis to paclitaxel. J Investig Allergol Clin Immunol 2010;20:170-1.
32. Nolte H, Kowal K, DuBuske Lawrence. Overview of skin testing for allergic disease [Web resource]. Boston, MA: Up- ToDate, Wolters Kluwer Health; n.d. [Current version available online at: http://www.uptodate.com/contents/overview-ofskin-testing-for-allergic-disease; cited July 31, 2012]
33. Brockow K, Romano A. Skin tests in the diagnosis of drug hypersensitivity reactions. Curr Pharm Des 2008;14:2778-91.
34. Tan J, Mehr S. Anaphylaxis to an ondansetron wafer. J Paediatr Child Health 2012;48:543-4.
35. Markman M, Zanotti K, Peterson G, Kulp B, Webster K, Belinson J. Expanded experience with an intradermal skin test to predict for the presence or absence of carboplatin hypersensitivity. J Clin Oncol 2003;21:4611-14.
36. Elligers KT, Davies M, Sanchis D, Ferencz T, Saif MW. Rechallenge with cisplatin in a patient with pancreatic cancer who developed a hypersensitivity reaction to oxaliplatin. Is skin test useful in this setting? JOP 2008;9:197-202.
37. Leguy-Seguin V, Jolimoy G, Coudert B, et al. Diagnostic and predictive value of skin testing in platinum salt hypersensitivity. J Allergy Clin Immunol 2007;119:726-30.
38. Syrigou E, Makrilia N, Vassias A, et al. Administration of cisplatin in three patients with carboplatin hypersensitivity: is skin testing useful? Anticancer Drugs 2010;21:333-8.
39. Robinson JB, Singh D, Bodurka-Bevers DC, Wharton JT, Gershenson DM, Wolf JK. Hypersensitivity reactions and the utility of oral and intravenous desensitization in patients with gynecologic malignancies. Gynecol Oncol 2001;82:550-8.
40. Hesterberg PE, Banerji A, Oren E, et al. Risk stratification for desensitization of patients with carboplatin hypersensitivity: clinical presentation and management. J Allergy Clin Immunol 2009;123:1262-7.e1.
41. Castells MC, Tennant NM, Sloane DE, et al. Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases. J Allergy Clin Immunol 2008;122:574-80.
42. Williams C, Bryant A. Short versus long duration infusions of paclitaxel for any advanced adenocarcinoma. Cochrane Database Syst Rev 2011;5:CD003911.
43. Hainsworth JD, Thompson DS, Greco FA. Paclitaxel by 1-hour infusion: an active drug in metastatic non-small-cell lung cancer. J Clin Oncol 1995;13:1609-14.
44. Polyzos A, Tsavaris N, Kosmas C, et al. Hypersensitivity reactions to carboplatin administration are common but not always severe: a 10-year experience. Oncology 2001;61:129-33.
45. Bhargava P, Gammon D, McCormick MJ. Hypersensitivity and idiosyncratic reactions to oxaliplatin. Cancer 2004;100:211-12.
46. Kidera Y, Satoh T, Ueda S, et al. High-dose dexamethasone plus antihistamine prevents colorectal cancer patients treated with modified folfox6 from hypersensitivity reactions induced by oxaliplatin. Int J Clin Oncol 2011;16:244-9.
47. BC Cancer Agency (bcca). BCCA Protocol Summary for Palliative Combination Chemotherapy for Metastatic Pancreatic Adenocarcinoma Using Irinotecan, Oxaliplatin, Fluorouracil and Folinic Acid (Leucovorin). Vancouver, BC: bcca; 2012.
48. Trudeau ME, Eisenhauer EA, Higgins BP, et al. Docetaxel in patients with metastatic breast cancer: a phase ii study of the National Cancer Institute of Canada-Clinical Trials Group. J Clin Oncol 1996;14:422-8.
49. Kwon JS, Elit L, Finn M, et al. A comparison of two prophylactic regimens for hypersensitivity reactions to paclitaxel. Gynecol Oncol 2002;84:420-5.
50. Rosenberg P, Andersson H, Boman K, et al. Randomized trial of single agent paclitaxel given weekly versus every three weeks and with peroral versus intravenous steroid premedication to patients with ovarian cancer previously treated with platinum. Acta Oncol 2002;41:418-24.
51. Syrigou E, Dannos I, Kotteas E, et al. Hypersensitivity reactions to docetaxel: retrospective evaluation and development of a desensitization protocol. Int Arch Allergy Immunol 2011;156:320-4.
52. Wang GS, Yang KY, Perng RP. Life-threatening hypersensitivity pneumonitis induced by docetaxel (Taxotere). Br J Cancer 2001;85:1247-50.
53. Burris HA. Optimal use of docetaxel (Taxotere): maximizing its potential. Anticancer Drugs 1996;7(suppl 2):25-8.
54. Burstein HJ, Manola J, Younger J, et al. Docetaxel administered on a weekly basis for metastatic breast cancer. J Clin Oncol 2000;18:1212-19.
55. Piccart MJ, Klijn J, Paridaens R, et al. Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: final results of a randomized study of the European Organization for Research and Treatment of Cancer Investigational Drug Branch for Breast Cancer. J Clin Oncol 1997;15:3149-55.
56. Chouhan JD, Herrington JD. Single premedication dose of dexamethasone 20 mg IV before docetaxel administration. J Oncol Pharm Pract 2011;17:155-9.
57. Feldweg AM, Lee CW, Matulonis UA, Castells M. Rapid desensitization for hypersensitivity reactions to paclitaxel and docetaxel: a new standard protocol used in 77 successful treatments. Gynecol Oncol 2005;96:824-9.
58. Ardavanis A, Tryfonopoulos D, Yiotis I, Gerasimidis G, Baziotis N, Rigatos G. Non-allergic nature of docetaxelinduced acute hypersensitivity reactions. Anticancer Drugs 2004;15:581-5.
59. Zanotti KM, Markman M. Prevention and management of antineoplastic-induced hypersensitivity reactions. Drug Saf 2001;24:767-79.
60. Lenz HJ. Management and preparedness for infusion and hypersensitivity reactions. Oncologist 2007;12:601-9.
61. Foote M. Using nanotechnology to improve the characteristics of antineoplastic drugs: improved characteristics of nabpaclitaxel compared with solvent-based paclitaxel. Biotechnol Annu Rev 2007;13:345-57.
62. Montana M, Ducros C, Verhaeghe P, Terme T, Vanelle P, Rathelot P. Albumin-bound paclitaxel: the benefit of this new formulation in the treatment of various cancers. J Chemother 2011;23:59-66.
63. Ibrahim NK, Desai N, Legha S, et al. Phase i and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res 2002;8:1038-44.
64. Ibrahim NK, Samuels B, Page R, et al. Multicenter phase ii trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer. J Clin Oncol 2005;23:6019-26.
65. Fader AN, Rose PG. Abraxane for the treatment of gynecologic cancer patients with severe hypersensitivity reactions to paclitaxel. Int J Gynecol Cancer 2009;19:1281-3.
66. Castells M. Desensitization for drug allergy. Curr Opin Allergy Clin Immunol 2006;6:476-81.
67. Lee CW, Matulonis UA, Castells MC. Rapid inpatient/outpatient desensitization for chemotherapy hypersensitivity: standard protocol effective in 57 patients for 255 courses. Gynecol Oncol 2005;99:393-9.
68. Limsuwan T, Castells MC. Outcomes and safety of rapid desensitization for chemotherapy hypersensitivity. Expert Opin Drug Saf 2010;9:39-53.
69. Confino-Cohen R, Fishman A, Altaras M, Goldberg A. Successful carboplatin desensitization in patients with proven carboplatin allergy. Cancer 2005;104:640-3.
70. Cortijo-Cascajares S, Nacle-Lopez I, Garcia-Escobar I, et al. Effectiveness of oxaliplatin desensitization protocols. Clin Transl Oncol 2013;15:219-25.
71. Rose PG, Fusco N, Smrekar M, Mossbruger K, Rodriguez M. Successful administration of carboplatin in patients with clinically documented carboplatin hypersensitivity. Gynecol Oncol 2003;89:429-33.
72. Gammon D, Bhargava P, McCormick MJ. Hypersensitivity reactions to oxaliplatin and the application of a desensitization protocol. Oncologist 2004;9:546-9.
73. Giacchetti S, Perpoint B, Zidani R, et al. Phase iii multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000;18:136-47.
74. Greco FA, Stroup SL, Hainsworth JD. Paclitaxel by 1-hour infusion in combination chemotherapy of stage iii non-small cell lung cancer. Semin Oncol 1995;22(suppl 9):75-7.
75. Lee C, Gianos M, Klaustermeyer WB. Diagnosis and management of hypersensitivity reactions related to common cancer chemotherapy agents. Ann Allergy Asthma Immunol 2009;102:179-87.
76. Gomez R, Harter P, Luck HJ, et al. Carboplatin hypersensitivity: does introduction of skin test and desensitization reliably predict and avoid the problem? A prospective single-center study. Int J Gynecol Cancer 2009;19:1284-7.
77. Zanotti KM, Rybicki LA, Kennedy AW, et al. Carboplatin skin testing: a skin-testing protocol for predicting hypersensitivity to carboplatin chemotherapy. J Clin Oncol 2001;19:3126-9.